U.S. markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.2200+0.0200 (+1.67%)
At close: 1:00PM EST

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
http://www.corbuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees141

Key Executives

NameTitlePayExercisedYear Born
Dr. Yuval CohenCEO & Director810.55kN/A1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBAChief Financial Officer520kN/A1958
Dr. Barbara WhiteHead of Research & Chief Medical Officer570.7kN/A1950
Ted JenkinsSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Mark A. TepperCo-Founder & ConsultantN/AN/A1957
Scott ConstantineSr. Director & Head of Clinical OperationsN/AN/AN/A
Mr. Craig Stuart Millian M.B.A.Chief Commercial OfficerN/AN/A1968
Sergei AtamasExec. Director of ResearchN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Corporate Governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.